Structural Stability and Prebiotic Properties of Resistant Starch Type 3 Increase Bile Acid Turnover and Lower Secondary Bile Acid Formation

2005 ◽  
Vol 53 (23) ◽  
pp. 9257-9267 ◽  
Author(s):  
Gerhard Dongowski ◽  
Gisela Jacobasch ◽  
Detlef Schmiedl
Keyword(s):  
Bile Acid ◽  
Structural Stability ◽  
Resistant Starch ◽  
Acid Formation ◽  
Secondary Bile Acid ◽  
Type 3

scholarly journals Hydrothermal treatment of Novelose 330 results in high yield of resistant starch type 3 with beneficial prebiotic properties and decreased secondary bile acid formation in rats

2006 ◽  
Vol 95 (6) ◽  
pp. 1063-1074 ◽  
Author(s):  
Gisela Jacobasch ◽  
Gerhard Dongowski ◽  
Detlef Schmiedl ◽  
Katrin Müller-Schmehl
Keyword(s):  
Bile Acids ◽  
Large Bowel ◽  
Resistant Starch ◽  
Distal Colon ◽  
Proximal Colon ◽  
Secondary Bile Acid ◽  
Mucosal Regeneration ◽  
Wide Range ◽  
Type 3 ◽  
Secondary Bile Acids

Annealing and heat-moisture treatment (HMT) are shown to be suitable methods to increase the yield of resistant starch type 3 (RS3) from Novelose 330 by up to 75%. Peak temperatures of approximately 121°C were used to produce to a sufficiently high thermal stability of the hydrothermal modified RS3 products for a wide range of applications. HMT significantly increased the crystallinity up to 40%.An in vivofeeding experiment with Wistar rats showed that fermentation of Novelose 330 dominated in the proximal colon, but degradation of HMT-Novelose was more dominant in the distal colon, leading to higher butyrate concentrations in this segment of the large bowel. Large-bowel surface and crypt length increased in the proximal colon in rats fed the Novelose 330-containing diet. In contrast, after the intake of HMT-Novelose, maximal values were found in the distal segment. The lower pH and higher butyrate concentration of the caecal and colonic contents significantlysuppressed the formation of secondary bile acids in RS3-fed rats. The formation of secondary bile acids was inhibited more strongly by HMT-Novelose than by Novelose 330. The Ki-67-immunopositive epithelial cells in the colon of RS3-fed rats indicated the establishment of an optimalbalance in the dynamic process of mucosal regeneration. HMT provides a method for the economical production of a high-quality RS3 with dominating prebiotic properties in the distal colon for health-promoting applications.

Pharmacological effects of secondary bile acid microparticles in diabetic murine model

2020 ◽  
Vol 16 ◽  
Author(s):  
Armin Mooranian ◽  
Nassim Zamani ◽  
Bozica Kovacevic ◽  
Corina Mihaela Ionescu ◽  
Giuseppe Luna ◽  
...  
Keyword(s):  
Bile Acid ◽  
Blood Glucose ◽  
Bile Acids ◽  
Lithocholic Acid ◽  
Diabetes Treatment ◽  
Secondary Bile Acid ◽  
Glucose Levels ◽  
Anti Inflammatory ◽  
Antidiabetic Effects

Aim: Examine bile acids effects in Type 2 diabetes. Background: In recent studies, the bile acid ursodeoxycholic acid (UDCA) has shown potent anti-inflammatory effects in obese patients while in type 2 diabetics (T2D) levels of the pro-inflammatory bile acid lithocholic acid were increased, and levels of the anti-inflammatory bile acid chenodeoxycholic acid were decreased, in plasma. Objective: Hence, this study aimed to examine applications of novel UDCA nanoparticles in diabetes. Methods: Diabetic balb/c adult mice were divided into three equal groups and gavaged daily with either empty microcapsules, free UDCA, or microencapsulated UDCA over two weeks. Their blood, tissues, urine, and faeces were collected for blood glucose, inflammation, and bile acid analyses. UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid modulation was not directly linked to diabetes treatment. Results: UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid modulation was not directly linked to diabetes treatment. Conclusion: Bile acids modulated the bile profile without affecting blood glucose levels.

scholarly journals Microbiome and PCOS: State-of-Art and Future Aspects

2021 ◽  
Vol 22 (4) ◽  
pp. 2048
Author(s):  
Pierluigi Giampaolino ◽  
Virginia Foreste ◽  
Claudia Di Filippo ◽  
Alessandra Gallo ◽  
Antonio Mercorio ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Bile Acid ◽  
Peptide Yy ◽  
Fecal Microbiota Transplantation ◽  
Polycystic Ovary ◽  
Current Evidence ◽  
Low Grade ◽  
Fecal Transplant ◽  
Secondary Bile Acid ◽  
First Case

Polycystic ovary syndrome (PCOS) is a complex and heterogeneous endocrine disease. The hypothesis that alterations in the microbiome are involved in the genesis of PCOS has been postulated. Aim of this review is to summarize the available literature data about the relationship between microbiome and PCOS. A search on PubMed and Medline databases was performed from inception to November 20Most of evidence has focused on the connection of intestinal bacteria with sex hormones and insulin-resistance: while in the first case, a relationship with hyperandrogenism has been described, although it is still unclear, in the second one, chronic low-grade inflammation by activating the immune system, with increased production of proinflammatory cytokines which interfere with insulin receptor function, causing IR (Insulin Resistance)/hyperinsulinemia has been described, as well as the role of gastrointestinal hormones like Ghrelin and peptide YY (PYY), bile acids, interleukin-22 and Bacteroides vulgatus have been highlighted. The lower genital tract microbiome would be affected by changes in PCOS patients too. The therapeutic opportunities include probiotic, prebiotics and synbiotics, as well as fecal microbiota transplantation and the use of IL-22, to date only in animal models, as a possible future drug. Current evidence has shown the involvement of the gut microbiome in PCOS, seen how humanized mice receiving a fecal transplant from women with PCOS develop ovarian dysfunction, immune changes and insulin resistance and how it is capable of disrupting the secondary bile acid biosynthesis. A future therapeutic approach for PCOS may involve the human administration of IL-22 and bile acid glycodeoxycholic acid.

scholarly journals An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer

2014 ◽  
pp. 1673 ◽  
Author(s):  
Hani Al-Salami ◽  
Armin Mooranian ◽  
Rebecca Negrulj ◽  
Nigel Chen-Tan ◽  
Gerald Watts ◽  
...  
Keyword(s):  
Bile Acid ◽  
Deoxycholic Acid ◽  
Permeation Enhancer ◽  
Secondary Bile Acid

Isolation of six novel 7-oxo- or urso-type secondary bile acid-producing bacteria from rat cecal contents

2017 ◽  
Vol 124 (5) ◽  
pp. 514-522 ◽  
Author(s):  
Sarinya Tawthep ◽  
Satoru Fukiya ◽  
Ja-Young Lee ◽  
Masahito Hagio ◽  
Yoshitoshi Ogura ◽  
...  
Keyword(s):  
Bile Acid ◽  
Secondary Bile Acid ◽  
Acid Producing Bacteria
Sign in / Sign up

Export Citation Format

Share Document